Is MannKind Corporation (MNKD) The Best Fundamentally Strong Penny Stock to Invest In Now?

MannKind Corporation (NASDAQ:MNKD) is among the best fundamentally strong penny stocks to invest in now. On April 8, TheFly reported that Truist trimmed the price target on MannKind Corporation (NASDAQ:MNKD) to $6 from $7 and reiterated a Buy rating. This downward revision in price was a part of a broader research note previewing Q1 earnings in the biotechnology space. The firm is among the 88% of analysts bullish on the stock, having a consensus one-year price target of $7.50.

In a research note, the analyst says that the sector is becoming less sensitive to regulatory and policy changes, with a recent pickup in deal activity having the potential to drive momentum through the rest of the year into midterms. What builds the case for MannKind Corporation (NASDAQ:MNKD) is a strong pipeline of catalysts that could power growth. These include the pediatric Afrezza label expansion PDUFA, scheduled for May 29; the Furoscix ReadyFlow autoinjector PDUFA, set for July 26; and the MNKD-201 in IPF updates, Truist noted.

Although MannKind Corporation (NASDAQ:MNKD) has consistently underperformed the S&P 500, the company’s YoY quarterly revenue growth of 45.80% and upside potential of nearly 165% position it among the best fundamentally strong penny stocks to invest in now.

MannKind Corporation (NASDAQ:MNKD) is a Connecticut-based biopharmaceutical company that specializes in chronic disease care. Incorporated in 1991, the company provides solutions for serious conditions, such as diabetes, pulmonary hypertension, and fluid overload.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.